These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30982469)

  • 21. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer.
    Okamoto T; duVerle D; Yaginuma K; Natsume Y; Yamanaka H; Kusama D; Fukuda M; Yamamoto M; Perraudeau F; Srivastava U; Kashima Y; Suzuki A; Kuze Y; Takahashi Y; Ueno M; Sakai Y; Noda T; Tsuda K; Suzuki Y; Nagayama S; Yao R
    Stem Cell Reports; 2021 Apr; 16(4):954-967. PubMed ID: 33711267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
    Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
    J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
    Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
    Lee JH; Lee SW
    Mol Biol Rep; 2019 Aug; 46(4):3835-3842. PubMed ID: 31028570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
    Dudal S; Hinton H; Giusti AM; Bacac M; Muller M; Fauti T; Colombetti S; Heckel T; Giroud N; Klein C; Umaña P; Benincosa L; Bachl J; Singer T; Bray-French K
    J Immunother; 2016 Sep; 39(7):279-89. PubMed ID: 27404941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
    Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
    Peng L; Oberst MD; Huang J; Brohawn P; Morehouse C; Lekstrom K; Baeuerle PA; Wu H; Yao Y; Coats SR; Dall'Acqua W; Damschroder M; Hammond SA
    PLoS One; 2012; 7(5):e36412. PubMed ID: 22574157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
    Cioce M; Fumagalli MR; Donzelli S; Goeman F; Canu V; Rutigliano D; Orlandi G; Sacconi A; Pulito C; Palcau AC; Fanciulli M; Morrone A; Diodoro MG; Caricato M; Crescenzi A; Verri M; Fazio VM; Zapperi S; Levrero M; Strano S; Grazi GL; La Porta C; Blandino G
    J Exp Clin Cancer Res; 2023 Jul; 42(1):170. PubMed ID: 37460938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
    Martínez-Sabadell A; Morancho B; Rius Ruiz I; Román Alonso M; Ovejero Romero P; Escorihuela M; Chicote I; Palmer HG; Nonell L; Alemany-Chavarria M; Klein C; Bacac M; Arribas J; Arenas EJ
    Cell Rep; 2022 Oct; 41(3):111430. PubMed ID: 36261015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
    Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
    Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
    Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
    Front Oncol; 2022; 12():883437. PubMed ID: 35719949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.